Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders

PHASE2CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Chronic HCV Infection
Interventions
DRUG

LDV/SOF

90/400 mg FDC tablet administered orally

DRUG

SOF

400 mg tablet administered orally once daily

DRUG

RBV

Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Trial Locations (13)

10029

New York

14621

Rochester

19104

Philadelphia

20007

Washington D.C.

30308

Atlanta

55407

Minneapolis

94143

San Francisco

95817

Sacramento

92103-8651

San Diego

02114

Boston

02115

Boston

07112

Newark

27599-7584

Chapel Hill

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY